Clinical Associate/Lecturer/CEO
Massachusetts General Hospital/Harvard Medical School/Ankyra Therapeutics
Boston, Massachusetts
Dr. Howard L. Kaufman has been a leading authority on tumor immunotherapy and oncolytic viruses for the treatment of melanoma. He led the first successful phase III trial of Talimogene laherparepvec (T-VEC). Dr. Kaufman received his MD degree from Loyola University, completed a residency in General Surgery at Boston University and fellowship training in Tumor Immunology and Surgical Oncology at the National Cancer Institute. He has previously held appointments as Chief of Surgical Oncology and Associate Director of the Herbert Irving Comprehensive Cancer Center at Columbia University, Director of the Rush University Cancer Center, and Associate Director for Clinical Science of the Rutgers Cancer Institute of New Jersey. Dr. Kaufman has published over 500 peer-reviewed scientific papers, books, review articles and abstracts. He is a member of numerous professional societies and served as President of the Society for Immunotherapy of Cancer. Dr. Kaufman was the recipient of several awards including the Daland Prize, MRF Humanitarian Award and UIC Distinguished Alumnus Award. He is CEO of Ankyra Therapeutics and maintains an academic appointment at Harvard Medical School. He is also Clinical Associate at Massachusetts General Hospital and is a Clinical Associate in Oncology at the Massachusetts Eye & Ear Infirmary.
Disclosure information not submitted.
Wednesday, October 19, 2022
10:00 AM – 10:30 AM ET